ABC | Volume 112, Nº6, Junho 2019

Artigo de Revisão Mesquita et al ICFEI – estado da arte Arq Bras Cardiol. 2019; 112(6):784-790 Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 9. Cheng RK, Cox M, Neely ML, Heidenreich PA, Bhatt DL, Eapen ZJ, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J. 2014; 168(5):721–30. 10. Coles AH, TisminetzkyM, Yarzebski J, LessardD, Gore JM, Darling CE, et al. Magnitude of and prognostic factors associated with 1-year mortality after hospital discharge for acute decompensated heart failure based on ejection fraction findings. J AmHeart Assoc. 2015;4(10):e002303. 11. Gómez-Otero I, Ferrero-Gregori A, Varela Román A, Seijas Amigo J, Pascual- Figal DA, et al. Mid-range ejection fraction does not permit risk stratification among patients hospitalized for heart failure. Rev Esp Cardiol (Engl Ed). 2017;70(5):338-46. 12. Farmakis D, Simitsis P, Bistola V, Triposkiadis F, Ikonomidis I, Katsanos S, et al. Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-termoutcome. Clin Res Cardiol. 2017;106(5):359–68. 13. Rickenbacher P, Kaufmann BA, Maeder MT, Bernheim A, Goetschalckx K, Pfister O, et al. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Eur J Heart Fail. 2017;19(12):1586–96. 14. Vedin O, LamCSP, Koh AS, Benson L, Teng THK, Tay WT, et al. Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study. Circ Heart Fail. 2017 Jun;10(6):e003875. 15. Pascual-Figal DA, Ferrero-Gregori A, Gomez-Otero I, Vazquez R, Delgado- Jimenez J, Alvarez-Garcia J, et al. Mid-range left ventricular ejection fraction: clinical profile and cause of death in ambulatory patients with chronic heart failure. Int J Cardiol. 2017 Aug;240:265–70. 16. Ghio S, Guazzi M, Scardovi AB, Klersy C, Clemenza F, Carluccio E, et al. Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction. Eur J Heart Fail. 2017;19(7):873–9. 17. Allen LA, Magid DJ, Gurwitz JH, Smith DH, Goldberg RJ, Saczynski J, et al. Risk factors for adverse outcomes by left ventricular ejection fraction in a contemporary heart failure population. Circ Heart Fail. 2013;6(4):635–46. 18. Jorge AJ, Rosa ML, Correia DM, Martins WA, Ceron DM, Coelho LC, et al. Evaluation of Quality of Life in Patients with and without Heart Failure in Primary Care. Arq Bras Cardiol. 2017;109(3):248–52. 19. Dunlay SM, Roger VL, Weston SA, Jiang R, Redfield MM. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail. 2012;5(6):720–6. 20. Clarke CL, Grunwald GK, Allen LA, Barón AE, Peterson PN, Brand DW, et al. Natural history of left ventricular ejection fraction in patients with heart failure. Circ Cardiovasc Qual Outcomes. 2013;6(6):680–6. 21. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50(8):768-77. 22. Bhambhani V, Kizer JR, Lima JA, van der Harst P, Bahrami H, Nayor M, et al. Predictors and outcomes of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2018;20(4):651–9. 23. Wang N, Hales S, Barin E, Tofler G. Characteristics and outcome for heart failure patients with mid-range ejection fraction. J Cardiovasc Med (Hagerstown);19(6):297–303. 24. Savarese G, Orsini N, Hage C, Dahlström U, Vedin O, Rosano GM, et al. Associations with and prognostic and discriminatory role of n-terminal pro–b-type natriuretic peptide in heart failure with preserved versus mid- range versus reduced ejection fraction. J Card Fail. 2018;24(6):365-74. 25. Lauritsen J, Gustafsson F, Abdulla J. Characteristics and long-term prognosis of patients with heart failure andmid-range ejection fraction comparedwith reduced and preserved ejection fraction: a systematic review and meta- analysis. ESC Heart Fail. 2018;5(4):685–94. 26. Guisado-EsparteroME, Salamanca-Bautista P, Aramburu-Bodas Ó, Conde- Martel A, Arias-Jiménez JL, Llàcer-Iborra P, et al. Heart failurewithmid-range ejection fraction in patients admitted to internal medicine departments: Findings from the RICA Registry. Int J Cardiol. 2018 Mar;255:124–8. 27. Lund LH, Claggett B, Liu J, LamCS, Jhund PS, RosanoGM, et al. Heart failure withmid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail. 2018;20(8):1230–9. 28. Johansson I, Dahlström U, Edner M, Näsman P, Rydén L, Norhammar A. Type 2 diabetes and heart failure: Characteristics and prognosis in preserved, mid-range and reduced ventricular function. Diab Vasc Dis Res. 2018;15(6):494-503. 29. Moliner P, Lupón J, Barallat J, de Antonio M, Domingo M, Núñez J, et al. Bio-profiling and bio-prognostication of chronic heart failurewithmid-range ejection fraction. Int J Cardiol. 2018 Apr;257:188–92. 30. Rastogi A, Novak E, Platts AE, MannDL. Epidemiology, pathophysiology and clinical outcomes for heart failurepatientswithamid-range ejection fraction. Eur J Heart Fail. 2017;19(12):1597–605. 31. Chioncel O, LainscakM, Seferovic PM, Anker SD, Crespo-LeiroMG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(12):1574-85. 32. Altaie S, KhalifeW. The prognosis of mid-range ejection fraction heart failure: a systematic review andmeta-analysis. ESCHeart Fail. 2018;5(6):1008-16. 33. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37(5):455–62. 34. Xin Y-G, Chen X, Zhao Y-N, Hu J, Sun Y, HuWY. Outcomes of spironolactone treatment in patients in Northeast China suffering from heart failure with mid-range ejection fraction. Curr Med Res Opin. 2019;35(4):561-8. 35. Hernandez AF, Hammill BG, O’Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF(OrganizedProgramtoInitiateLifesavingTreatmentinHospitalized PatientswithHeartFailure)Registry.JAmCollCardiol2009;53(2):184–92. 36. Konstam MA. Seeking therapeutic precision in heart failure: is ejection fraction really the way? Deconstructing the CHARM of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2018;20(8):1240–2. 37. Cleland JG, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJ, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018;39(1):26–35. 38. GwagHB,LeeGY,ChoiJO,LeeHY,KimJJ,HwangKK,etal.FateofAcuteHeart FailurePatientsWithMid-RangeEjectionFraction.CircJ.2018;82(8):2071–8. 39. Abdul-Rahim AH, Shen L, Rush CJ, Jhund PS, Lees KR, McMurray JJ, et al. Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. Eur J Heart Fail. 2018;20(7):1139–45. 40. Dunlay SM, Roger VL, Weston SA, Jiang R, Redfield MM. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail. 2012;5(6):720–6. 41. Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59(11):998–1005. 42. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, andMortality in Type 2Diabetes. N Engl J Med. 201;373(22):2117–28. 790